Conference Coverage: ASCO 2022 – Focus on Breast Cancer
Expert perspectives on the latest therapeutic developments, treatment approaches, and implications for clinical decision-making coming out of the ASCO 2022 conference.
FACULTY CHAIR
Adam Brufsky, MD, PhD, FACP
Magee-Womens Cancer Program at the UPMC Hillman Cancer Center, Pittsburgh, PA, USA
FACULTY MEMBERS
Giuseppe Curigliano, MD, PhD
University of Milano, Italy
Mark D. Pegram, MD
Stanford Cancer Institute, Stanford, CA, USA
Peter A. Kaufman, MD
The University of Vermont Medical Center, Burlington, VT, USA
Joseph Gligorov, MD, PhD
APHP Tenon, Paris, France
Guy H. Jerusalem, MD, PhD
University of Liège/CHU de Liège, Belgium
KEY TAKEAWAYS AND STRATEGIC INSIGHTS
- Updates on Neoadjuvant Therapies for Breast Cancer
- CDK4/6 Inhibitors in the Treatment of HR+, HER2– Breast Cancer
- Novel Therapeutic Approaches for HR+, HER2– Breast Cancer
- Evolving Treatments for HER2+, HER2–, and HER2-Low Breast Cancer